Back to All Resources

Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations

December 7, 2020

62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition

Targeting MYD88-Mutant DLBCL with IRAKIMiDs Version 2
View Presentation
Area of Focus
Oncology
Programs
Other
Indications
Other
Development Stage
Pre-clinical Data
Share
LinkedInXFacebookEmailCopy Link

You may also be interested in these resources

August 24, 2022
Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications
ACS Fall 2022
Other
View Resource
June 26, 2022
Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology
37th ACS National Medicinal Chemistry Symposium
Other
View Resource